Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Curadev announced it has licensed its novel lead small molecule Stimulator of Interferon Genes (STING) agonist and associated patents to Takeda Pharmaceutical.
read more
CURE Pharmaceutical has named Dr. Vered Gigi, Vice President of Strategy and Business Development.
read more
Wednesday, March 13, 2019
CURE has broadened its DEA license as an authorized manufacturer of Schedule 1 substances to include both cannabis plant extracts and synthetic CBD.
read more
CURE announced it has received their first purchase order from their recently announced agreement with Meroven for the development of OTF delivery for several molecules.
read more
CURE Pharmaceutical has closed on the previously announced acquisition of Chemistry Holdings, a formulation technology company that is develops delivery systems for a variety of industries.
read more
Wednesday, October 09, 2019
CURE announces the expansion of its oral drug delivery product line creating CUREform™ which includes CUREfilm®.
read more
CURE Pharmaceutical announced a collaboration with PMI, a subsidiary of Factoria Bogar in Guadalajara, Mexico.
read more
Wednesday, February 05, 2020
CURE Pharmaceutical has signed an exclusive licensing agreement with ReLeaf Europe, one of Europe’s pharmaceutical groups specialized in medicinal cannabis products.
read more
Friday, February 05, 2021
CureVac and Rentschler Biopharma announced the companies have initiated the set-up of manufacturing capabilities for CureVac´s COVID-19 vaccine, CVnCoV.
read more
CureVac AG has confirmed internal efforts are focused on the development of a coronavirus vaccine.
read more
Monday, December 02, 2019
CureVac has received manufacturing authorization for clinical trial materials produced under GMP from Regierungspräsidium Tübingen for the company’s scaled up GMP III production suite.
read more
Friday, December 04, 2020
CureVac and Wacker Chemie have signed a contract for the manufacturing of CureVac’s COVID-19 vaccine candidate CVnCoV.
read more
Berkeley Lights, Inc. and Curia, formerly AMRI, a contract research, development and manufacturing organization (CDMO), announced Curia’s adoption of The Beacon® Optofluidic system and workflows from Berkeley Lights to accelerate and expand its ...
read more
Curia, a contract research, development and manufacturing organization, announced a collaboration with Corning Incorporated to expand and accelerate continuous-flow development and manufacturing programs for the chemical and biopharmaceutical ...
read more
Curia, formerly AMRI, announced that they will collaborate on a robust development platform for Replicate’s srRNA therapeutics. The strategic collaboration unites two RNA therapeutics industry leaders.
read more